AGIO vs IMCR
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AGIO's Advanced Deterministic Scorecard reveals severe financial distress: a Piotroski F-Score of 1/9 indicates poor operational and financial health, while the absence of an Altman Z-Score raises red flags for potential bankruptcy risk. Despite strong revenue growth of 86.1% YoY, the company reports a 0.00% profit margin, negative operating margin of -608.89%, and negative ROE of -30.20%, signaling deep operational inefficiencies. Insider selling activity totaling $2.06M over six months, with multiple officer sales, underscores lack of confidence from within the organization. The stock trades at a premium valuation (Price/Sales of 30.20) with no earnings or cash flow support, and its 52-week high is 65% above current levels, indicating overvaluation relative to fundamentals.
IMCR exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9, indicating poor financial health and operational deterioration. While the company maintains an impressive gross margin of 96.53% and positive revenue growth of 24.3%, these are offset by a catastrophic year-over-year EPS decline of 452.9% and a bearish insider sentiment. There is a stark disconnect between the aggressive analyst target price of $63.86 and the actual deterministic data, which suggests a high-risk profile characterized by consistent earnings misses and insider liquidation.
Compare Another Pair
Related Comparisons
AGIO vs IMCR: Head-to-Head Comparison
This page compares Agios Pharmaceuticals, Inc. (AGIO) and Immunocore Holdings plc (IMCR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.